



1/54


FIG. 1






3/54

FIG. 2B




4/54

FIG. 3




5/54

FIG. 4A



6/54


FIG. 4B



7/54

FIG. 5A


HNT-34 cells



8/54


FIG. 5B

MOLM-13 cells




9/54

FIG. 6




10/54

FIG. 7A




11/54

FIG. 7B




12/54

FIG. 7C



13/54

FIG. 8A



14/54

FIG. 8B





FIG. 9A




16/54

FIG. 9B

- IL-3R α
-△- GM-CSFR α
—▼— IL-3R α (1-100)
—■— IL-3R α (101-306)

huCD123-6Gv4.7 Ab binding curve




	EC ₅₀
IL-3R α	1.06E-10
IL-3R α (101-306)	1.45E-10

17/54

FIG. 9C

- IL-3R α
 - - $\triangle$ - - GM-CSFR α
 —▼— IL-3R α (1-100)
 —■— IL-3R α (101-306)




	EC ₅₀
IL-3R α	2.74E-10
IL-3R α (101-306)	8.52E-10

18/54

FIG. 9D


—○— IL-3R α
 -△- GM-CSFR α
 —▼— IL-3R α (1-100)
 —■— IL-3R α (101-306)

chCD123-14 Ab binding curve



	EC ₅₀
IL-3R α	6.55E-10
IL-3R α (1-100)	4.79E-10

FIG. 9E




	EC ₅₀
IL-3R α	2.701E-11
IL-3R α (1-100)	3.061E-11

20/54

FIG. 9F

- IL-3R α
 - - Δ - - GM-CSFR α
 —▼— IL-3R α (1-100)
 —■— IL-3R α (101-306)


mu6H6 Ab binding curve



	EC ₅₀
IL-3R α	7.2E-11
IL-3R α (1-100)	1.22E-10

21/54


FIG. 9G



	EC ₅₀
IL-3R α	8.12E-11
IL-3R α (1-100)	1.52E-10

22/54

FIG. 10



● huCD123-6Rv1.1-CX1-1-DM1

● huCD123-6Rv1.1-CX1-1-DM1 with blocking concentration (500nM) of huCD123-6

23/54







FIG. 11B






26/54


FIG. 11D





28/54

FIG. 12A




- huCD123-6Rv1.1-sSPDB-DGN462
- ◆ huCD123-6Rv1.1-sSPDB-D1
- huCD123-6Rv1.1-D3
- ▲ huCD123-6Rv1.1-D2

29/54


FIG. 12B

———— Median value



30/54


FIG. 13A



31/54


FIG. 13B

- huCD123-6Gv4.6-CysMab-D5
- huCD123-6Gv4.6-CysMab-D5 + blocking Ab
- huCD123-6Gv4.6-D2
- huCD123-6Gv4.6-D2 + blocking Ab




32/54

FIG. 13C




33/54

FIG. 14A




34/54


FIG. 14B



35/54

FIG. 14C





36/54




FIG. 17




FIG. 18

Treatment Status	MDR status	CD33 ABC	CD123 ABC
Pre Treatment	neg	11,391	8,930
Pre Treatment	NT	4,320	2,000
Pre Treatment	pos	740	3,800
Pre Treatment	pos	3,500	4,200
Pre Treatment	neg	1,000	4,600
Pre Treatment	neg	6,111	1,360
Pre Treatment	pos	700	1,000
Pre Treatment	neg	10,500	2,600
Pre Treatment	pos	20,820	2,174
Pre Treatment	neg	10,513	16,118
Pre Treatment	pos	640	3,400
Refractory	pos	600	1,400
Relapsed	neg	28,907	6,793
Relapsed/Refractory	pos	28,782	2,252
Relapsed/Refractory	pos	9,268	11,132
Median		6,111	3,400






FIG. 19





Treatment Group	T/C	PR	CR
Vehicle	-	0/6	0/6
huCD123-sSPDB-D1 (1 µg/kg)	30%	0/6	0/6
huCD123-lysine linked-D2 (1 µg/kg)	3%	4/6	3/6
huCD123-CysMab-D5 (1 µg/kg)	0%	6/6	5/6
huCD123-sSPDB-D1 (3 µg/kg)	0%	6/6	6/6
huCD123-lysine linked-D2 (3 µg/kg)	0%	6/6	6/6
huCD123-CysMab-D5 (3 µg/kg)	0%	6/6	6/6
chKTI-sSPDB-D1 (3 µg/kg)	0%	6/6	6/6
chKTI-lysine linked-D2 (3 µg/kg)	34%	1/6	1/6
huKTI-CysMab-D5 (1 µg/kg)	80%	0/6	0/6
huKTI-CysMab-D5 (3 µg/kg)	48%	1/6	1/6





FIG. 22



44/54

FIG. 23




FIG. 24






FIG. 25




47/54

FIG. 26



48/54

FIG. 27



49/54







FIG. 29



51/54



52/54



53/54

FIG. 32

